Abstract
The inhibition of Histamine N-methyltransferase (HNMT) has been recently shown to play potential roles in the treatment of neurodegenerative diseases, allergic vasoconstriction and anaphylactic manifestation. For designing and discovering new potential human HNMT inhibitors, the ligand (Hypo1) and structure-based (SB_Hypo1) pharmacophore models were developed based on the most active inhibitors and the highest resolution crystal structure of HNMT, respectively. After validating the reliability of both models with decoy dataset, they were separately used as 3D-query for virtual screening to retrieve potential hits from Maybridge and Chembridge databases. Subsequently, the hit compounds were subjected to filter by applying the ADMET, molecular docking and consensus score. Finally, 10 hits (five compounds from each model) were suggested as potential leads based on the structural diversity, good fit value, favorable binding interactions and high docking consensus score. The obtained novel hits from this study may facilitate to identify and optimize new leads for HNMT inhibition.
Keywords: Consensus scoring, Histamine N-methyltransferase, HipHop, Molecular docking, Structurebased, Virtual screening, Ligand, pharmacophore modeling, Histamine, Hypo1, HNMT, 3D-query, Chembridge databases, ADMET, GPCR, HDC
Letters in Drug Design & Discovery
Title: Ligand and Structure-Based Pharmacophore Modeling for the Discovery of Potential Human HNMT Inhibitors
Volume: 9 Issue: 1
Author(s): Pavadai Elumalai, Hsuan-Liang Liu, Zheng-Li Zhou, Jian-Hua Zhao, Wilson Chen, Chih-Kuang Chuang, Wei-Bor Tsai and Yih Ho
Affiliation:
Keywords: Consensus scoring, Histamine N-methyltransferase, HipHop, Molecular docking, Structurebased, Virtual screening, Ligand, pharmacophore modeling, Histamine, Hypo1, HNMT, 3D-query, Chembridge databases, ADMET, GPCR, HDC
Abstract: The inhibition of Histamine N-methyltransferase (HNMT) has been recently shown to play potential roles in the treatment of neurodegenerative diseases, allergic vasoconstriction and anaphylactic manifestation. For designing and discovering new potential human HNMT inhibitors, the ligand (Hypo1) and structure-based (SB_Hypo1) pharmacophore models were developed based on the most active inhibitors and the highest resolution crystal structure of HNMT, respectively. After validating the reliability of both models with decoy dataset, they were separately used as 3D-query for virtual screening to retrieve potential hits from Maybridge and Chembridge databases. Subsequently, the hit compounds were subjected to filter by applying the ADMET, molecular docking and consensus score. Finally, 10 hits (five compounds from each model) were suggested as potential leads based on the structural diversity, good fit value, favorable binding interactions and high docking consensus score. The obtained novel hits from this study may facilitate to identify and optimize new leads for HNMT inhibition.
Export Options
About this article
Cite this article as:
Elumalai Pavadai, Liu Hsuan-Liang, Zhou Zheng-Li, Zhao Jian-Hua, Chen Wilson, Chuang Chih-Kuang, Tsai Wei-Bor and Ho Yih, Ligand and Structure-Based Pharmacophore Modeling for the Discovery of Potential Human HNMT Inhibitors, Letters in Drug Design & Discovery 2012; 9 (1) . https://dx.doi.org/10.2174/157018012798192955
DOI https://dx.doi.org/10.2174/157018012798192955 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Endoplasmic Reticulum Protein Quality Control in Neurodegenerative Disease: The Good, the Bad and the Therapy
Current Medicinal Chemistry Polymeric Drug Delivery Approaches for Colon Targeting: A Review
Drug Delivery Letters Patient-Specific Induced Pluripotent Stem Cell Models in Mitochondrial Diseases
Current Stem Cell Research & Therapy Flt3 Receptor Tyrosine Kinase as a Drug Target in Leukemia
Current Pharmaceutical Design Clinical, Genetic, and Neuroimaging Features of Early Onset Alzheimer Disease: The Challenges of Diagnosis and Treatment
Current Alzheimer Research MicroRNAs in Genetic Disease: Rethinking the Dosage
Current Gene Therapy Allosteric Regulators of the Proteasome: Potential Drugs and a Novel Approach for Drug Design
Current Medicinal Chemistry Glycosphingolipid Structure and Function in Membranes
Current Organic Chemistry Modulation of Expression and Activity of ABC Transporters by the Phytoestrogen Genistein. Impact on Drug Disposition
Current Medicinal Chemistry Tumor-Targeting Peptides and Small Molecules as Anti-Cancer Agents to Overcome Drug Resistance
Current Medicinal Chemistry Diabetes Exacerbates Nanoparticles Induced Brain Pathology
CNS & Neurological Disorders - Drug Targets Mycoplasma pneumoniae Attachment Proteins and Toxins as Mediators in Disease Production
Current Pediatric Reviews Nanotherapeutics in Neuropathologies: Obstacles, Challenges and Recent Advancements in CNS Targeted Drug Delivery Systems
Current Neuropharmacology Disturbed Homeostasis in Patients with Acute Psychosis
Current Psychiatry Reviews Colloidal Polymeric Nanoparticles and Brain Drug Delivery
Current Drug Delivery Inhibition of mTOR Signaling by Quercetin in Cancer Treatment and Prevention
Anti-Cancer Agents in Medicinal Chemistry Apoptosis: A Key in Neurodegenerative Disorders
Current Neurovascular Research Dysfunctions of the Diffusional Membrane Pathways Mediated Hemichannels in Inherited and Acquired Human Diseases
Current Vascular Pharmacology A Study of Tryptophan Metabolism via Serotonin in Ventricular Cerebrospinal Fluid in HIV-1 Infection Using a Neuroendoscopic Technique
Current HIV Research Non-Nucleoside HIV-1 Reverse Transcriptase (RT) Inhibitors: Past, Present, and Future Perspectives
Current Pharmaceutical Design